Drug Profile
Research programme: cystic fibrosis therapy - GlaxoSmithKline/McGill University
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; McGill University
- Developer McGill University
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cystic-fibrosis in Canada
- 28 Jan 2011 Early research in Cystic fibrosis in Canada (unspecified route)